A Randomised, Double-Blind, Placebo Controlled, Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Repeat Dose of Inhaled ETD001 in People With Cystic Fibrosis
Latest Information Update: 26 Mar 2025
At a glance
- Drugs ETD 001 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Enterprise Therapeutics
Most Recent Events
- 19 Nov 2024 According to an Enterprise Therapeutics media release, enrollment in this study is expected to complete in 2025.
- 24 Jul 2024 According to an Enterprise Therapeutics media release, company announced the dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.
- 12 Jun 2024 According to an Enterprise Therapeutics media release, trial is scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summer 2024.